Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204957 · ClinicalTrials.gov registry record · Phase 1
Brown Seaweed as a Breast Cancer Preventive
A Phase 1 study, sponsored by University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01204957: Completed Phase 1 study, sponsored by University of South Carolina.
NCT01204957 is a Phase 1 study that has completed, run by University of South Carolina. The registered enrollment target is 33 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01204957, a Phase 1 study, has completed, sponsored by University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Japanese postmenopausal women in Japan have about one ninth the rate of American postmenopausal women. Rates of breast cancer double even after just ten years among Japanese women who migrate to the US. Diet is thought to be an important factor, and the investigators were interested in whether dietary seaweed, with and without soy supplements, could influence known biomarkers of breast cancer risk in American women.
Primary Outcome
6 wk seaweed followed by 1 wk seaweed plus soy; Or 6 wk placebo followed by 1 wk soy 3 wk washout period then crossover to alternate arm
Interventions
- DIETARY_SUPPLEMENT Seaweed and Soy Protein
- DIETARY_SUPPLEMENT Placebo and Soy Protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 1998-10 |
| Est. Completion | 1999-03 |
| Phase | Phase 1 |
What the finished NCT01204957 record still lists
NCT01204957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which Seaweed and Soy Protein is the first listed.
NCT01204957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01204957 about?
NCT01204957 is a clinical study titled "Brown Seaweed as a Breast Cancer Preventive". Japanese postmenopausal women in Japan have about one ninth the rate of American postmenopausal women. Rates of breast cancer double even after just ten years among Japanese women who migrate to the US. Diet is thought to be an important factor, and the investigators were interested in whether dieta...
What is the current status of trial NCT01204957?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 1998-10. Estimated completion is 1999-03.
What interventions are being tested in trial NCT01204957?
The interventions under investigation include: Seaweed and Soy Protein (DIETARY_SUPPLEMENT), Placebo and Soy Protein (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01204957?
This trial is sponsored by University of South Carolina, which has 157 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01204957's enrollment target sits among peer trials
33 1280th of 2000 higher than 705 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia